Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
about
Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancerTherapeutic approaches in the management of locally advanced rectal cancer.Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α.Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future.Current status of intensified neo-adjuvant systemic therapy in locally advanced rectal cancer.The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies.Rectal cancer radiotherapy: towards European consensus.Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.Toward the non-surgical management of locally advanced rectal cancer.Controversies and challenges regarding the impact of radiation therapy on survival.Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line.Cetuximab induces eme1-mediated DNA repair: a novel mechanism for cetuximab resistance.Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer.Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03)
P2860
Q27007505-CDE0FDE0-91DA-4B82-87D3-5B9A3C049B7FQ34234928-88F51B45-43AD-4ADA-B3C1-B3CEF64BE122Q34255956-BE944BE7-ABED-40BD-8731-63FF4C18E382Q35920508-694B5451-C1FF-4887-AEDC-36601A7FCCAFQ35987944-E9859012-BC13-4F68-8B7F-21D598036F08Q37015715-6F2A1CD4-4D1D-4CE0-8997-F5D39744751DQ37038486-4D902FC9-CAA4-4CAC-B9AC-87127CDD09ECQ37789029-9B2FC9CE-179E-4B95-8FC7-85F03A880A9DQ37861572-4C253392-6852-4B25-82DB-4C941805565AQ37998384-B5334CEE-9018-4042-BEB9-3B1AC726407CQ38035079-46A29DF2-22AC-43FA-8E2B-0340D311E7AAQ39115018-777F6645-9F86-4CB3-8AAD-912F14FBD8CBQ41816821-125CC7E9-84C6-4920-B26B-5C8F08D600C8Q53239683-111FF041-CEE2-4911-9719-BF817C14B7DFQ55070724-0CFB56D1-7905-43F6-B6D2-595DB4092A8BQ56357033-DA7AE664-42FA-41BE-8737-4144697AFCA6
P2860
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
@en
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
@nl
type
label
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
@en
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
@nl
prefLabel
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
@en
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
@nl
P2093
P2860
P1433
P1476
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
@en
P2093
Mark Harrison
Rob Glynne-Jones
Suzy Mawdsley
P2860
P304
P356
10.3109/02841860903536010
P577
2010-04-01T00:00:00Z